ARCHIVES

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

This article is from The Cancer Letter archive.

Vol. 32 No. 28 | July 21, 2006

Download PDF Visit The Full Archive

Related Articles

New Therapies For Genitourinary Cancers In Clinical Testing Presented At ASCO

July 25, 2003

NIH Orders Duke Medical Center To Stop Enrollment In Human Research Studies

May 14, 1999

NCI Cooperative Group, Cancer Center Trials Listed

August 29, 2008

Final Issue Of 1988

December 9, 1988

ORI Finds Researcher Falsified Records

February 9, 1996

Facilities Survey Finrs $25 Million a Year for Five Years Needed From NCI By Year 1990

March 8, 1985